This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
by Zacks Equity Research
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
BDX Stock Declines Following Class I Classification for Alaris Recall
by Zacks Equity Research
BD's recall of Alaris infusion pumps following software issues has been classified as the most severe recall by the FDA. A suspension of sales may hurt the top line going forward.
Cardinal Health (CAH) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
Cardinal Health (CAH) concluded the recent trading session at $132.75, signifying a -0.35% move from its prior day's close.
ABT Stock to Gain From FDA IDE Approval for Its Coronary IVL System
by Zacks Equity Research
Abbott's Coronary IVL System wins FDA IDE nod, offering a potential new treatment for arterial calcium blockages.
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval
by Zacks Equity Research
ALC secures CE Mark for Clareon Vivity IOL, bringing advanced presbyopia-correcting lens technology to Europe, enhancing visual outcomes with cutting-edge innovation.
ALC Stock Rises Following the Merger Agreement With LENSAR
by Zacks Equity Research
Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.
Should You Consider Retaining PBH Stock in Your Portfolio Now?
by Zacks Equity Research
Investors remain optimistic about Prestige Consumer due to its strong focus on brand building and strategic acquisition.
Illumina's AGD Project Completes 250,000 Whole Genomes: Stock to Gain?
by Zacks Equity Research
ILMN-NashBio's AGD initiative achieves the milestone of completing 250,000 whole genomes.
New Thrombectomy Product Launches Support PEN Stock Amid Macro Issues
by Zacks Equity Research
Penumbra expects to materially increase both revenues and profitability in the company's international business in the next few years.
GEHC Stock Falls Despite New Launch to Boost Breast Cancer Diagnosis
by Zacks Equity Research
GE HealthCare aims to deliver optimal outcomes with its innovative, patient-friendly and efficient AI-driven technology via its latest product offering.
BDX Shares May Climb as GalaFLEX LITE Trial Hits Key Milestone
by Zacks Equity Research
BD advances its clinical trial for the bioabsorbable GalaFLEX LITE scaffold, aiming to improve outcomes in breast implant revision surgeries and patient recovery.
Here's Why You Should Hold GEHC Stock in Your Portfolio for Now
by Zacks Equity Research
GE HealthCare's continued focus on innovations, acquisitions and partnerships raises optimism about the stock.
Insulet Gains 62.9% in a Year: What's Driving the Stock?
by Zacks Equity Research
PODD's shares rise on the back of its innovative Omnipod 5 system and impressive market expansion. However, the unfavorable macroeconomic scenario is concerning.
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
by Zacks Equity Research
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.
PODD Stock Gains Following the Launch of Omnipod 5 in Australia
by Zacks Equity Research
Insulet announces the commercial launch of Omnipod 5 AID system in Australia, with Dexcom G6 and G7 CGM sensor compatibility.
Should You Consider Retaining ZBH Stock in Your Portfolio Now?
by Zacks Equity Research
Zimmer Biomet's robust Knee business appears promising. However, a dull macroeconomic condition adds to the worry.
HealthEquity Stock Tumbles Despite the Launch of Assist Benefits Suite
by Zacks Equity Research
HQY launches Assist Suite to integrate personalized support, simplify benefits, and enhance engagement, aiming to reduce costs and improve outcomes.
Here's Why You Should Retain PacBio Stock in Your Portfolio Now
by Zacks Equity Research
PACB continues to deliver growth from its unique technologies amid macroeconomic concerns.
GEHC Stock Gains Following Cardiology Solutions Portfolio Expansion
by Zacks Equity Research
GE HealthCare aims to enhance efficiency and precision care for multiple types of cardiac procedures through the introduction of improved interventional solutions.
PODD Stock to Gain From Favorable RADIANT Trial Results for Omnipod 5
by Zacks Equity Research
Insulet unveils positive RADIANT trial clinical data for its Omnipod 5 at the 18th international conference on ATTD.
New Product Launches to Support HOLX Stock Amid Macro Issues
by Zacks Equity Research
Hologic's Surgical business has been driving strong broad-based performance by expanding access to technologies in new global markets.
TMO Stock Set to Gain From the Launch of New Vulcan Automated Lab
by Zacks Equity Research
Thermo Fisher introduces the Vulcan Automated Lab to transform semiconductor analysis.
GEHC Stock Gains in Pre-Market Following Tie-Up Expansion With NVIDIA
by Zacks Equity Research
GE HealthCare aims to unlock automated solutions that enhance efficiency, easing the burden of increased volumes and staff shortages on healthcare professionals.
HQY Stock Falls as Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
HealthEquity surpasses fourth-quarter revenue expectations on robust HSA growth. It also provided fiscal 2026 guidance.
Here's Why You Should Retain AMED Stock in Your Portfolio Now
by Zacks Equity Research
Amedisys' high Quality of Patient Care and Patient Satisfaction star ratings bring optimism to investors. Yet, a dull macroeconomic condition adds to the worry.